FIELD: medicine, pharmaceuticals.
SUBSTANCE: invention relates to composition for treatment of cyclooxygenase-5 related disorder or condition containing 5-methyl-2-(2'-chloro-6-fluoroaniline)-phenylacetic acid or pharmaceutically acceptable salt thereof. Said composition represents pharmaceutical composition of rapid release and has effective and safe anti-inflammation action for about 24 hours after single administering.
EFFECT: effective and safe pharmaceutical composition with anti-inflammation action.
20 cl, 11 tbl, 3 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINIG LUMIRACOXIBE | 2002 |
|
RU2329801C2 |
| PHARMACEUTICAL COMPOSITIONS | 2003 |
|
RU2318497C2 |
| COMPOSITIONS CONTAINING SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | 2002 |
|
RU2333754C2 |
| PHARMACEUTICAL COMPOSITION FOR USING IN THERAPY OF MALIGNANT NEOPLASM COMPRISING COMBINATION OF BISPHOSPHONATE, COX-2 INHIBITOR AND TAXOL | 2002 |
|
RU2317819C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING 5-METHYL-2-(2′-CHLORO-6′- FLUOROANILINE)PHENYLACETIC ACID | 2004 |
|
RU2363462C2 |
| TAPENTADOL COMPOSITIONS FOR PAIN MANAGEMENT | 2008 |
|
RU2497512C2 |
| SPECIFIC 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES | 1998 |
|
RU2186762C2 |
| PHENYLACETIC ACID DERIVATIVES AS COG-2 (CYCLOOXYGENASE-2) INHIBITORS | 2007 |
|
RU2454402C2 |
| SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT | 2013 |
|
RU2673818C2 |
| COMBINED COMPOSITION | 2010 |
|
RU2455983C1 |
